Literature DB >> 21270168

Differential sensitivities of retroviruses to integrase strand transfer inhibitors.

Yasuhiro Koh1, Kenneth A Matreyek, Alan Engelman.   

Abstract

Integrase inhibitors are emerging anti-human immunodeficiency virus (HIV) drugs, and multiple retroviruses and transposable elements were evaluated here for susceptibilities to raltegravir (RAL) and elvitegravir (EVG). All viruses, including primate and nonprimate lentiviruses, a Betaretrovirus, a Gammaretrovirus, and the Alpharetrovirus Rous sarcoma virus (RSV), were susceptible to inhibition by RAL. EVG potently inhibited all lentiviruses and intermediately inhibited Betaretrovirus and Gammaretrovirus infections yet was basically ineffective against RSV. Substitutions based on HIV type 1 (HIV-1) resistance changes revealed that integrase residue Ser150 contributed significantly to the resistance of RSV. The drugs intermediately inhibited intracisternal A-particle retrotransposition but were inactive against Sleeping Beauty transposition and long interspersed nucleotide element 1 (LINE-1) retrotransposition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270168      PMCID: PMC3067883          DOI: 10.1128/JVI.02541-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Determination of L1 retrotransposition kinetics in cultured cells.

Authors:  E M Ostertag; E T Prak; R J DeBerardinis; J V Moran; H H Kazazian
Journal:  Nucleic Acids Res       Date:  2000-03-15       Impact factor: 16.971

2.  Human foamy virus reverse transcription that occurs late in the viral replication cycle.

Authors:  A Moebes; J Enssle; P D Bieniasz; M Heinkelein; D Lindemann; M Bock; M O McClure; A Rethwilm
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 3.  First Mariner Mos1 transposase inhibitors.

Authors:  N Bouchet; J Bischerour; S Germon; J Guillard; M Dubernet; M C Viaud-Massuard; O Delelis; V Ryabinin; Y Bigot; C Augé-Gouillou
Journal:  Mini Rev Med Chem       Date:  2009-04       Impact factor: 3.862

4.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

5.  Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.

Authors:  Yasuhiro Koh; Hillel Haim; Alan Engelman
Journal:  Antimicrob Agents Chemother       Date:  2010-11-08       Impact factor: 5.191

6.  Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Authors:  Ila R Singh; John E Gorzynski; Daria Drobysheva; Leda Bassit; Raymond F Schinazi
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

Review 7.  Elvitegravir: a new HIV integrase inhibitor.

Authors:  Kazuya Shimura; Eiichi N Kodama
Journal:  Antivir Chem Chemother       Date:  2009-10-19

8.  Trex1 prevents cell-intrinsic initiation of autoimmunity.

Authors:  Daniel B Stetson; Joan S Ko; Thierry Heidmann; Ruslan Medzhitov
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

9.  The SET complex acts as a barrier to autointegration of HIV-1.

Authors:  Nan Yan; Peter Cherepanov; Janet E Daigle; Alan Engelman; Judy Lieberman
Journal:  PLoS Pathog       Date:  2009-03-06       Impact factor: 6.823

10.  Molecular architecture of the Mos1 paired-end complex: the structural basis of DNA transposition in a eukaryote.

Authors:  Julia M Richardson; Sean D Colloms; David J Finnegan; Malcolm D Walkinshaw
Journal:  Cell       Date:  2009-09-18       Impact factor: 41.582

View more
  19 in total

Review 1.  Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Authors:  Alan N Engelman
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

2.  Retroviral Integrase Structure and DNA Recombination Mechanism.

Authors:  Alan Engelman; Peter Cherepanov
Journal:  Microbiol Spectr       Date:  2014

3.  Enhanced autointegration in hyperstable simian immunodeficiency virus capsid mutants blocked after reverse transcription.

Authors:  Christopher Tipper; Joseph Sodroski
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

4.  Rous sarcoma virus synaptic complex capable of concerted integration is kinetically trapped by human immunodeficiency virus integrase strand transfer inhibitors.

Authors:  Krishan K Pandey; Sibes Bera; Sergey Korolev; Mary Campbell; Zhiqi Yin; Hideki Aihara; Duane P Grandgenett
Journal:  J Biol Chem       Date:  2014-05-28       Impact factor: 5.157

5.  Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.

Authors:  Takele Argaw; Winston Colon-Moran; Carolyn Wilson
Journal:  Xenotransplantation       Date:  2016-03-29       Impact factor: 3.907

6.  Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents.

Authors:  Hiroaki Togami; Kazuya Shimura; Munehiro Okamoto; Rokusuke Yoshikawa; Takayuki Miyazawa; Masao Matsuoka
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

Review 7.  The structural biology of HIV-1: mechanistic and therapeutic insights.

Authors:  Alan Engelman; Peter Cherepanov
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

Review 8.  Structure and function of retroviral integrase.

Authors:  Goedele N Maertens; Alan N Engelman; Peter Cherepanov
Journal:  Nat Rev Microbiol       Date:  2021-07-09       Impact factor: 60.633

Review 9.  Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.

Authors:  Alan N Engelman; Peter Cherepanov
Journal:  FEBS J       Date:  2020-06-22       Impact factor: 5.542

10.  Development of a robust cell-based high-throughput screening assay to identify targets of HIV-1 viral protein R dimerization.

Authors:  Courtney Zych; Alexander Domling; Velpandi Ayyavoo
Journal:  Drug Des Devel Ther       Date:  2013-05-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.